CTOs on the Move

BZAM Cannabis

www.bzamheadquarters.com

 
Headquartered in Vancouver, BC, BZAM Cannabis is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Triangle Chapter of the American Red Cross

Triangle Chapter of the American Red Cross is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rocky Mountain Health Care Services

Rocky Mountain PACE is a healthcare organization that provides coordinated health care services for older adults through the PACE model of care (Program of All-Inclusive Care for the Elderly). Their mission is to improve lives, optimize wellness, and p...

Legacy Good Samaritan Hospital and Medical Center

Legacy Good Samaritan Hospital and Medical Center is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TSN Labs Inc

TSN Labs Inc is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.